<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180333</url>
  </required_header>
  <id_info>
    <org_study_id>PNA-20120309-V1</org_study_id>
    <nct_id>NCT03180333</nct_id>
  </id_info>
  <brief_title>The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers</brief_title>
  <official_title>The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Yipinhong Pharmaceutical CO.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Yipinhong Pharmaceutical CO.,LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conduct in Chinese healthy adult subjects:1.To observe the safety and tolerability of&#xD;
      multiple-dose oral administration of different doses of PNA;2.By measuring the changing drug&#xD;
      concentration in the plasma and urine after a single oral administration of different doses&#xD;
      of PNA on the condition of fasting, the pharmacokinetic parameters of the single dose are&#xD;
      estimated;3.By measuring the changing drug concentration in the plasma of PNA after a&#xD;
      multiple-dose oral administration on the condition of fasting, the pharmacokinetic parameters&#xD;
      of multiple-dose are estimated, and a basis for dosage regimens of the clinical research&#xD;
      phase Ⅱ is provided;4.To study the effects of diet on the pharmacokinetic parameters via the&#xD;
      changes of concentration of PNA in plasma after high-fat and high-calorie food.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into three parts:&#xD;
&#xD;
        1. The tolerance test of randomized，double-blind, placebo-controlled multiple-dose oral&#xD;
           administrations.2 dosage groups are set up.Each group contains 8 subjects,evenly&#xD;
           composed of men and women.The beginning dosage of the study is 160mg/L.Subjects who have&#xD;
           successfully completed tests of the beginning dosage group and passed the safety&#xD;
           assessment will enter the test of next dosage group(320mg/L) according to the same&#xD;
           method.&#xD;
&#xD;
        2. Pharmacokinetic tests(single/multiple dose) .(1)Single dosing pharmacokinetic tests.36&#xD;
           eligible healthy subjects are selected. Each group has 12 people, evenly composed of men&#xD;
           and women. After taking 80mg/160mg/320mg of PNA orally in fasting state, blood and urine&#xD;
           samples are taken to be tested and analyzed, in order to study the pharmacokinetic&#xD;
           characteristics of single-dose administrations.(2)Multiple dosing pharmacokinetic&#xD;
           tests.In the single-dose administration trial, respectively choose 10 subjects (evenly&#xD;
           composed of men and women) in middle and high-dose group (160mg qd、320mg qd).After the&#xD;
           single-dose administration,inspecte the pharmacokinetic characteristics with 6-day&#xD;
           continuous administration. Blood samples are taken to test the trough drug concentration&#xD;
           of pre-dose in the morning of the 3rd, 4th, 5th day after administration, and the 6th&#xD;
           morning before and after the administration, to study the steady state concentration and&#xD;
           the fluctuation coefficient of the trough to peak drug concentration after&#xD;
           multiple-dose, and to find out whether there exists the effect of drug storage and / or&#xD;
           induction of drug enzyme.&#xD;
&#xD;
        3. The effect of diet.Choose 12 qualified healthy subjects (normally evenly composed of men&#xD;
           and women), a randomized two-way cross-over design is used, respectively orally take 160&#xD;
           mg of PNA before and after meal, and to study the effect of diet on pharmacokinetic via&#xD;
           blood collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TEAEs</measure>
    <time_frame>day 1 to day 14</time_frame>
    <description>Frequency of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>Area under the plasma concentration versus time curve of PNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>Maximum Plasma Concentration of PNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>day 1 to day 7</time_frame>
    <description>The time required while plasma concentration is reduced by half of PNA</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>PNA 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNA placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNA 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNA 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNA 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNA</intervention_name>
    <arm_group_label>PNA 1</arm_group_label>
    <arm_group_label>PNA 2</arm_group_label>
    <arm_group_label>PNA 3</arm_group_label>
    <arm_group_label>PNA 4</arm_group_label>
    <other_name>Metacavir Enteric-coated Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNA placebo</intervention_name>
    <arm_group_label>PNA placebo</arm_group_label>
    <other_name>Metacavir Enteric-coated Capsules placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged 18 to 45 years old ;&#xD;
&#xD;
          2. Body mass index (BMI) above/equal 19 and below 24 kg/m2;&#xD;
&#xD;
          3. Child bearing potential, has a negative serum pregnancy test at screening period, and&#xD;
             agrees to use contraceptions consistently and correctly in 14 days after dosing;&#xD;
&#xD;
          4. Subjects with no cardiovascular, liver, kidney, digestive tract, nervous and mental&#xD;
             and other acute or chronic diseases that may affect the safety and pharmacokinetic of&#xD;
             drug;&#xD;
&#xD;
          5. Signed informed consent voluntarily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects not meet the inclusion criteria;&#xD;
&#xD;
          2. Abnormal clinically significant laboratory results;&#xD;
&#xD;
          3. Abnormal clinically significant electrocardiogram (ECG);&#xD;
&#xD;
          4. A positive hepatitis B surface antigen, hepatitis C or HIV test result;&#xD;
&#xD;
          5. History of hypersensitivity or allergy to any of the study drugs or to drugs of&#xD;
             similar chemical classes;&#xD;
&#xD;
          6. Addicted to smoking and drinking;&#xD;
&#xD;
          7. Drink in 36 hours before post-dosing of study drug;&#xD;
&#xD;
          8. Ingest any foods or beverages which may affect pharmacokinetics;&#xD;
&#xD;
          9. Drug abuse,a history of poisoning;&#xD;
&#xD;
         10. Subjects who had received other medications within 2 weeks prior to the first&#xD;
             administration of Investigational Product，and the original and main metabolites were&#xD;
             not completely eliminated ;&#xD;
&#xD;
         11. Subjects who participated in any other clinical trials within 3 months prior to the&#xD;
             first administration of Investigational Product;&#xD;
&#xD;
         12. Subjects who had suffered from hemorrhage or blood donation over 200ml will be&#xD;
             excluded;&#xD;
&#xD;
         13. Subjects over exercised accompanied with fatigue and muscle aches within 1 week period&#xD;
             to the first administration of Investigational Product;&#xD;
&#xD;
         14. Children,women who are pregnant,lactating,with childbearing potential and who are&#xD;
             using acyeterions;&#xD;
&#xD;
         15. Subjects in the opinion of the investigator, could not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongwei Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruifang Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

